Published in Am J Cardiol on December 15, 2004
Breath Test to Predict Breast Cancer and Outcome of Mammography | NCT04755829
Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer (2009) 1.99
Advances in electronic-nose technologies developed for biomedical applications. Sensors (Basel) (2011) 1.66
Overcoming the challenges of studying conservation physiology in large whales: a review of available methods. Conserv Physiol (2013) 0.93
Rapid point-of-care breath test for biomarkers of breast cancer and abnormal mammograms. PLoS One (2014) 0.89
Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. Clin Dev Immunol (2013) 0.83
Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension. PLoS One (2014) 0.81
Effects of dietary nutrients on volatile breath metabolites. J Nutr Sci (2013) 0.80
Predicting co-morbidities in chemically sensitive individuals from exhaled breath analysis. Interdiscip Toxicol (2012) 0.78
Advances in gas chromatographic methods for the identification of biomarkers in cancer. J Cancer (2012) 0.76
A new method to evaluate macaque health using exhaled breath: A case study of M. tuberculosis in a BSL-3 setting. J Appl Physiol (1985) (2017) 0.75
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation (2007) 4.67
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol (2009) 4.03
Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation (2010) 3.83
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med (2004) 3.44
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Detection of lung cancer with volatile markers in the breath. Chest (2003) 3.09
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03
Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol (2003) 2.91
Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant (2006) 2.86
Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol (2004) 2.63
Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. Am J Obstet Gynecol (2004) 2.62
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation (2003) 2.57
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation (2009) 2.57
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol (2010) 2.52
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation (2010) 2.45
Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol (2007) 2.41
Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol (2003) 2.35
Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation (2007) 2.34
Caring for a spouse with end-stage heart failure through implantation of a left ventricular assist device as destination therapy. Heart Lung (2013) 2.17
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail (2011) 2.15
Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol (2011) 2.10
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail (2008) 2.09
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm (2011) 1.93
Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest (2002) 1.93
CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2002) 1.92
Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation (2009) 1.84
Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant (2006) 1.84
Volatile markers of breast cancer in the breath. Breast J (2003) 1.82
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail (2012) 1.79
Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail (2009) 1.77
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol (2004) 1.75
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.74
Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol (2011) 1.69
Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med (2005) 1.67
Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant (2011) 1.67
The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol (2007) 1.63
Diffuse optical correlation tomography of cerebral blood flow during cortical spreading depression in rat brain. Opt Express (2006) 1.62
EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol (2005) 1.62
Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark (2007) 1.60
High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol (2003) 1.59
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb) (2006) 1.57
Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol (2009) 1.57
A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol (2012) 1.55
Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant (2003) 1.54
Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy. JACC Cardiovasc Interv (2008) 1.53
A comparison of atrial arrhythmias after heart or double-lung transplantation at a single center: insights into the mechanism of post-operative atrial fibrillation. J Am Coll Cardiol (2009) 1.51
Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol (2004) 1.49
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail (2010) 1.49
Increased oxidative stress in younger as well as in older humans. Clin Chim Acta (2003) 1.47
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace (2012) 1.46
Value of drug-eluting stents in cardiac transplant recipients. Am J Cardiol (2009) 1.45
Effects of nasal continuous positive airway pressure on oxygen body stores in patients with Cheyne-Stokes respiration and congestive heart failure. Chest (2003) 1.44
Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail (2012) 1.43
Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant (2006) 1.42
Effect of simulated postprandial hyperglycemia on coronary blood flow in cardiac transplant recipients. Am J Physiol Heart Circ Physiol (2007) 1.41
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Simple method to eliminate interference between ventricular assist devices and cardiac rhythm devices. Pacing Clin Electrophysiol (2009) 1.40
In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol (2002) 1.33
Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation (2005) 1.32
Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb) (2010) 1.31
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (2003) 1.31
Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation (2005) 1.31
High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol (2004) 1.30
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant (2008) 1.29
Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant (2010) 1.28
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol (2004) 1.27
Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat (2006) 1.26
Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg (2008) 1.25
Increased breath biomarkers of oxidative stress in diabetes mellitus. Clin Chim Acta (2004) 1.25
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
Left ventricular collapse secondary to pericardial effusion treated with pericardicentesis and percutaneous pericardiotomy in severe pulmonary hypertension. Echocardiography (2008) 1.23
Volatile biomarkers in the breath of women with breast cancer. J Breath Res (2010) 1.23
Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation (2004) 1.21
Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis (2002) 1.21
Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta (2008) 1.21